Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Moolec Science S.A. (MLEC) Stock Forecast & Price Prediction Cayman Islands | NASDAQ | Healthcare | Biotechnology
$0.47
+0.02 (3.79%)Did MLEC Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if MooLec is one of their latest high-conviction picks.
MLEC has shown a year-to-date change of -94.1% and a 1-year change of -94.9%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MLEC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for MLEC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 30, 2024 | Maxim Group | Anthony Vendetti | Buy | Initiates | $6.00 |
| Nov 22, 2022 | Cantor Fitzgerald | Overweight | Upgrade | $N/A | |
| Oct 20, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 26, 2022 | Wedbush | Outperform | Maintains | $N/A | |
| Sep 7, 2022 | Capital One | Overweight | Initiates | $N/A |
The following stocks are similar to MooLec based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Moolec Science S.A. has a market capitalization of $5.08M with a P/E ratio of -0.2x. The company generates $5.63M in trailing twelve-month revenue with a 8.4% profit margin.
Revenue growth is +69.7% quarter-over-quarter, while maintaining an operating margin of -127.9% and return on equity of -107.3%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Biotechnology company revolutionizing agri-food sector.
Moolec Science S.A. generates revenue by producing animal proteins through molecular farming techniques that utilize plant-based systems. This innovative approach allows the company to create sustainable and ethical food options that cater to the growing demand for environmentally friendly protein sources in the food industry.
By functioning at the intersection of agriculture and biology, Moolec Science aims to reduce the environmental impact of protein production while addressing global sustainability agendas. Their technology has the potential to transform traditional livestock farming, making food production processes more efficient and climate-friendly.
Healthcare
Biotechnology
52
Mr. Gaston Paladini M.B.A.
Cayman Islands
2023
Moolec Science SA is non-compliant with Nasdaq Listing Rule 5250(c)(1) for not filing its Annual Report on Form 20-F by the deadline due to complexities post-business combination.
Moolec Science's non-compliance with Nasdaq listing rules due to delayed financial reporting raises concerns about transparency and potential risks, impacting investor confidence and stock performance.
Consumer staples sector shows oversold stocks, indicating potential buying opportunities for investors in undervalued companies.
Oversold stocks in consumer staples indicate potential bargains, suggesting likely price recoveries and solid returns, attracting value-focused investors.
Moolec Science Limited received regulatory approval for its safflower GLASO technology in Argentina, expanded U.S. acreage, and appointed a new CFO to enhance leadership.
Regulatory approval for Moolec's GLASO technology in Argentina and U.S. acreage expansion signal growth potential, enhancing revenue prospects and leadership strength, crucial for investor confidence.
Moolec Science SA (NASDAQ: MLEC) has successfully completed its strategic business combination with Bioceres Group, Gentle Technologies, and Nutrecon, enhancing its position in sustainable food-tech innovation.
Moolec's strategic business combination enhances its market position in sustainable food tech, potentially driving growth and profitability, which could attract investor interest and influence stock performance.
Moolec Science Limited received a Notice of Allowance from the USPTO for its Piggy Sooyโข technology, which enables soybean plants to produce porcine hemeproteins in their seeds.
The patent allowance for Moolec's Piggy Sooyโข technology could lead to a competitive edge in the plant-based protein market, potentially increasing revenue and attracting investor interest.
Moolec Science SA (NASDAQ: MLEC) has regained compliance with Nasdaq's Bid Price Rule after a 1-for-10 reverse stock split on May 14, 2025, with shares now closing above $1.
Moolec Science regaining compliance with Nasdaq listing rules and executing a reverse stock split signals improved financial stability, potentially boosting investor confidence and stock value.
Analyst forecasts for Moolec Science S.A. (MLEC) are not currently available. The stock is trading at $0.47.
According to current analyst ratings, MLEC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.47. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for MLEC are not currently available. The stock is trading at $0.47.
Moolec Science S.A. generates revenue by producing animal proteins through molecular farming techniques that utilize plant-based systems. This innovative approach allows the company to create sustainable and ethical food options that cater to the growing demand for environmentally friendly protein sources in the food industry.
Price targets from Wall Street analysts for MLEC are not currently available. The stock is trading at $0.47.
Price targets from Wall Street analysts for MLEC are not currently available. The stock is trading at $0.47.
The overall analyst consensus for MLEC is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
Stock price projections, including those for Moolec Science S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.